Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
about
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
P2860
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biliary effects of liraglutide ...... l in type 2 diabetes patients.
@en
Biliary effects of liraglutide ...... l in type 2 diabetes patients.
@nl
type
label
Biliary effects of liraglutide ...... l in type 2 diabetes patients.
@en
Biliary effects of liraglutide ...... l in type 2 diabetes patients.
@nl
prefLabel
Biliary effects of liraglutide ...... l in type 2 diabetes patients.
@en
Biliary effects of liraglutide ...... l in type 2 diabetes patients.
@nl
P2093
P2860
P50
P356
P1476
Biliary effects of liraglutide ...... al in type 2 diabetes patients
@en
P2093
Albert K Groen
Daniël H van Raalte
Djuna L Cahen
Lennart Tonneijck
Mark H H Kramer
Max Nieuwdorp
Michaela Diamant
P2860
P304
P356
10.1111/DOM.12748
P577
2016-08-30T00:00:00Z